Christopher van Dyck

2.7k total citations · 1 hit paper
30 papers, 1.9k citations indexed

About

Christopher van Dyck is a scholar working on Physiology, Radiology, Nuclear Medicine and Imaging and Cognitive Neuroscience. According to data from OpenAlex, Christopher van Dyck has authored 30 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Physiology, 6 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Cognitive Neuroscience. Recurrent topics in Christopher van Dyck's work include Alzheimer's disease research and treatments (11 papers), Computational Drug Discovery Methods (5 papers) and Cholinesterase and Neurodegenerative Diseases (4 papers). Christopher van Dyck is often cited by papers focused on Alzheimer's disease research and treatments (11 papers), Computational Drug Discovery Methods (5 papers) and Cholinesterase and Neurodegenerative Diseases (4 papers). Christopher van Dyck collaborates with scholars based in United States, Japan and Sweden. Christopher van Dyck's co-authors include Ronald G. Thomas, Robert B. Innis, John Seibyl, Paul Aisen, Kenneth Marek, Clifford R. Jack, Michael W. Weiner, James E. Galvin, Edward Nelson and Lynne Shinto and has published in prestigious journals such as JAMA, Neurology and Biological Psychiatry.

In The Last Decade

Christopher van Dyck

29 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease

2010 558 citations Joseph F. Quinn, Rema Raman et al. JAMA profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher van Dyck United States	13	590	574	454	358	287	30	1.9k
Chunjiu Zhong China	25	918 1.6×	811 1.4×	357 0.8×	160 0.4×	200 0.7×	61	2.8k
Jill K. Morris United States	23	1.1k 1.8×	345 0.6×	236 0.5×	462 1.3×	79 0.3×	83	2.1k
Mehmet Cansev Türkiye	23	570 1.0×	219 0.4×	340 0.7×	177 0.5×	326 1.1×	69	1.8k
Patrícia Nardin Brazil	31	602 1.0×	324 0.6×	500 1.1×	546 1.5×	97 0.3×	50	2.8k
Stanley I. Rapoport United States	21	542 0.9×	142 0.2×	404 0.9×	292 0.8×	190 0.7×	46	2.0k
Qun Wang China	22	474 0.8×	438 0.8×	437 1.0×	297 0.8×	56 0.2×	110	2.2k
B.L. Scott United States	20	311 0.5×	1.0k 1.8×	543 1.2×	83 0.2×	340 1.2×	47	2.2k
David Robertson United States	30	643 1.1×	494 0.9×	506 1.1×	174 0.5×	72 0.3×	70	2.7k
Gabriel C. Léger United States	21	532 0.9×	467 0.8×	360 0.8×	518 1.4×	33 0.1×	43	2.0k
Marı́a C. Carrillo United States	17	499 0.8×	343 0.6×	491 1.1×	597 1.7×	51 0.2×	45	2.4k

Countries citing papers authored by Christopher van Dyck

Since Specialization

Citations

This map shows the geographic impact of Christopher van Dyck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher van Dyck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher van Dyck more than expected).

Fields of papers citing papers by Christopher van Dyck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher van Dyck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher van Dyck. The network helps show where Christopher van Dyck may publish in the future.

Co-authorship network of co-authors of Christopher van Dyck

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher van Dyck. A scholar is included among the top collaborators of Christopher van Dyck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher van Dyck. Christopher van Dyck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Irizarry, Michael C., Christopher van Dyck, David Li, et al.. (2025). The Lecanemab Clarity AD Open-Label Extension in Early Alzheimer’s Disease (P1-3.003). Neurology. 104(7_Supplement_1). 1 indexed citations

2.

Dyck, Christopher van. (2024). The Development of Neuroimaging Methodologies to Assist in the Diagnosis and Treatment of Alzheimer’s Disease. Biological Psychiatry. 95(10). S25–S25.

3.

Holmes, Sophie, Sule Tinaz, Mika Naganawa, et al.. (2024). Synaptic loss and its association with symptom severity in Parkinson’s disease. npj Parkinson s Disease. 10(1). 42–42. 13 indexed citations

4.

Datta, Dibyadeep, Feng Liang, Nicolas R. Barthélemy, et al.. (2023). Chronic GCPII (glutamate‐carboxypeptidase‐II) inhibition reduces pT217Tau levels in the entorhinal and dorsolateral prefrontal cortices of aged macaques. Alzheimer s & Dementia Translational Research & Clinical Interventions. 9(4). e12431–e12431. 8 indexed citations

5.

Xiao, Ting, et al.. (2018). Exploring Age-Related Changes in Resting State Functional Connectivity of the Amygdala: From Young to Middle Adulthood. Frontiers in Aging Neuroscience. 10. 209–209. 25 indexed citations

6.

Chen, Ming-Kai, Adam P. Mecca, Jean‐Dominique Gallezot, et al.. (2018). Correlation of neuronal function and synaptic density in Alzheimer’s disease. 59. 412–412. 2 indexed citations

7.

Turner, Raymond Scott, Ronald J. Thomas, Suzanne Craft, et al.. (2015). Resveratrol is safe and well-tolerated in individuals with mild-moderate dementia due to Alzheimer’s disease. (S33.009). Neurology. 84(14_supplement). 1 indexed citations

8.

Galasko, Douglas, J. Simon Bell, Jessica Mancuso, et al.. (2014). Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease. Neurology. 82(17). 1536–1542. 149 indexed citations

9.

Salloway, Stephen, Vlad Coric, Mark Brody, et al.. (2011). O4‐06‐08: Safety and tolerability of BMS‐708163 in a phase II study in mild‐to‐moderate Alzheimer's disease. Alzheimer s & Dementia. 7(4S_Part_20). 4 indexed citations

10.

Quinn, Joseph F., Rema Raman, Ronald G. Thomas, et al.. (2010). Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease. JAMA. 304(17). 1903–1903. 558 indexed citations breakdown →

11.

Harrington, Conn, Sharon Sawchak, Carl Chiang, et al.. (2009). P4‐299: Effects Of Rosiglitazone‐extended Release As Adjunctive Therapy To Acetylcholinesterase Inhibitors Over 48 Weeks On Cognition In Apoe4‐stratified Subjects With Mild‐to‐moderate Alzheimer's Disease. Alzheimer s & Dementia. 5(4S_Part_17). 7 indexed citations

12.

Zdanys, Kristina, et al.. (2006). Apolipoprotein E ε4 Allele Is Unrelated to Cognitive or Functional Decline in Alzheimer’s Disease: Retrospective and Prospective Analysis. Dementia and Geriatric Cognitive Disorders. 22(1). 73–82. 63 indexed citations

13.

Grundman, Michael, Clifford R. Jack, Ronald C. Petersen, et al.. (2003). Hippocampal Volume Is Associated with Memory but not Nonmemory Cognitive Performance in Patients with Mild Cognitive Impairment. Journal of Molecular Neuroscience. 20(3). 241–248. 59 indexed citations

14.

Lappalainen, Jaakko, Henry R. Kranzler, Robert T. Malison, et al.. (2002). A Functional Neuropeptide Y Leu7Pro Polymorphism Associated With Alcohol Dependence in a Large Population Sample From the United States. Archives of General Psychiatry. 59(9). 825–825. 128 indexed citations

15.

Grundman, Michael, Drahomira Sencakova, Clifford R. Jack, et al.. (2002). Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. Journal of Molecular Neuroscience. 19(1-2). 23–27. 126 indexed citations

16.

Marek, Kenneth, Robert B. Innis, Christopher van Dyck, et al.. (2001). [ ¹²³ I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression. Neurology. 57(11). 2089–2094. 275 indexed citations

17.

Laruelle, Marc, Anissa Abi‐Dargham, Christopher van Dyck, et al.. (2000). Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [123I]β-CIT. Biological Psychiatry. 47(5). 371–379. 107 indexed citations

18.

Gelernter, Joel, Christopher van Dyck, Daniël P. van Kammen, et al.. (1997). Ciliary neurotrophic factor null allele frequencies in schizophrenia, affective disorders, and Alzheimer's disease. American Journal of Medical Genetics. 74(5). 497–500. 16 indexed citations

19.

Gelernter, Joel, Christopher van Dyck, Daniël P. van Kammen, et al.. (1997). Ciliary neurotrophic factor null allele frequencies in schizophrenia, affective disorders, and Alzheimer's disease. American Journal of Medical Genetics. 74(5). 497–500. 1 indexed citations

20.

Marek, Kenneth, John Seibyl, Sami S. Zoghbi, et al.. (1996). [sup 123 I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology. 46(1). 231–237. 287 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact